Lasmiditan | CAS#439239-90-4 | 613677-28-4 | 5-HT(1F) receptor agonist

MedKoo Cat#: 319811 | Name: Lasmiditan

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lasmiditan, also known as COL-144 and LY573144, is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist (K1=2.21 μM) without vasoconstrictor activity that seemed effective when given as an intravenous infusion in a proof-of-concept migraine study. Lasmiditan showed efficacy in its primary endpoint, with a 2-hour placebo-subtracted headache response of 28.8%, though with frequent reports of dizziness, paresthesias, and vertigo. This product is not available (controlled substance).

Chemical Structure

Lasmiditan

CAS#439239-90-4 (free base)

Theoretical Analysis

MedKoo Cat#: 319811

Name: Lasmiditan

CAS#: 439239-90-4 (free base)

Chemical Formula: C19H18F3N3O2

Exact Mass: 377.1351

Molecular Weight: 377.37

Elemental Analysis: C, 60.47; H, 4.81; F, 15.10; N, 11.14; O, 8.48

Price and Availability

This product was removed for the commercial reasons.

Related CAS #

439239-90-4 (free base) 613677-28-4 (HCl) 439239-92-6 (succinate) 2171471-98-8 (HCl dihydrate) 2171471-99 (HCl hydrate)

Synonym

COL-144; COL144; COL 144; LY573144; LY-573144; LY 573144; Lasmiditan.

IUPAC/Chemical Name

2,4,6-Trifluoro-N-(6-((1-methylpiperidine-4-yl)carbonyl)pyridin-2-yl)benzamide

InChi Key

XEDHVZKDSYZQBF-UHFFFAOYSA-N

InChi Code

InChI=1S/C19H18F3N3O2/c1-25-7-5-11(6-8-25)18(26)15-3-2-4-16(23-15)24-19(27)17-13(21)9-12(20)10-14(17)22/h2-4,9-11H,5-8H2,1H3,(H,23,24,27)

SMILES Code

O=C(NC1=NC(C(C2CCN(C)CC2)=O)=CC=C1)C3=C(F)C=C(F)C=C3F

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 377.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Clemow DB, Hochstetler HM, Dong Y, Hauck P, Peres MFP, Ailani J. Effect of a change in lasmiditan dose on efficacy and safety in patients with migraine. Postgrad Med. 2021 Mar 17:1-11. doi: 10.1080/00325481.2020.1860619. Epub ahead of print. PMID: 33730977. 2: Kaytser V, Zhang P. Non-interacting, Non-opioid, and Non-barbiturate Containing Acute Medication Combinations in Headache: A Pilot Combinatorics Approach Based on DrugBank Database. Front Neurol. 2021 Feb 17;12:632830. doi: 10.3389/fneur.2021.632830. PMID: 33679591; PMCID: PMC7925628. 3: Parikh S. Lasmiditan for acute treatment of migraine. Drugs Today (Barc). 2021 Feb;57(2):89-100. doi: 10.1358/dot.2021.57.2.3238326. PMID: 33656015. 4: Berger AA, Winnick A, Popovsky D, Kaneb A, Berardino K, Kaye AM, Cornett EM, Kaye AD, Viswanath O, Urits I. Lasmiditan for the Treatment of Migraines With or Without Aura in Adults. Psychopharmacol Bull. 2020 Oct 15;50(4 Suppl 1):163-188. PMID: 33633424; PMCID: PMC7901123. 5: Ferrari A, Rustichelli C. Rational Use of Lasmiditan for Acute Migraine Treatment in Adults: A Narrative Review. Clin Ther. 2021 Feb 16:S0149-2918(21)00047-3. doi: 10.1016/j.clinthera.2021.01.020. Epub ahead of print. PMID: 33608115. 6: Tsai M, Nery ESM, Kerr L, Khanna R, Komori M, Dennehy EB, Wilbraham D, Winner P. Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine. Clin Pharmacokinet. 2021 Feb 10. doi: 10.1007/s40262-020-00966-z. Epub ahead of print. PMID: 33565026. 7: Peters GL, Hennessey EK. Rimegepant: acute treatment for migraine headaches. Pain Manag. 2021 May;11(3):259-266. doi: 10.2217/pmt-2020-0090. Epub 2021 Feb 8. PMID: 33550872. 8: Ashina M, Reuter U, Smith T, Krikke-Workel J, Klise SR, Bragg S, Doty EG, Dowsett SA, Lin Q, Krege JH. Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study. Cephalalgia. 2021 Mar;41(3):294-304. doi: 10.1177/0333102421989232. Epub 2021 Feb 4. PMID: 33541117. 9: Drugs for Migraine. Med Lett Drugs Ther. 2020 Oct 5;62(1608):153-160. PMID: 33434187. 10: Mecklenburg J, Raffaelli B, Neeb L, Sanchez Del Rio M, Reuter U. The potential of lasmiditan in migraine. Ther Adv Neurol Disord. 2020 Oct 21;13:1756286420967847. doi: 10.1177/1756286420967847. PMID: 33403005; PMCID: PMC7739205. 11: Negro A, Martelletti P. Novel synthetic treatment options for migraine. Expert Opin Pharmacother. 2020 Dec 28:1-16. doi: 10.1080/14656566.2020.1862793. Epub ahead of print. PMID: 33369482. 12: Marshall C, Torro J. Lasmiditan (Reyvow) for the Treatment of Acute Migraine. Am Fam Physician. 2020 Dec 15;102(12):756-757. PMID: 33320510. 13: Szkutnik-Fiedler D. Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of New Anti-Migraine Drugs-Lasmiditan, Gepants, and Calcitonin- Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies. Pharmaceutics. 2020 Dec 3;12(12):1180. doi: 10.3390/pharmaceutics12121180. PMID: 33287305; PMCID: PMC7761673. 14: Singh RBH, VanderPluym JH, Morrow AS, Urtecho M, Nayfeh T, Roldan VDT, Farah MH, Hasan B, Saadi S, Shah S, Abd-Rabu R, Daraz L, Prokop LJ, Murad MH, Wang Z. Acute Treatments for Episodic Migraine [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Dec. Report No.: 21-EHC009. PMID: 33411427. 15: L'Italien GJ, Croop R, Stock DA. Pain Freedom at 2-8 Hours With Lasmiditan: A Comparison With Rimegepant and Ubrogepant: A Response. Headache. 2020 Nov;60(10):2611-2612. doi: 10.1111/head.13973. PMID: 33249583. 16: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Lasmiditan. 2020 Nov 16. PMID: 33104315. 17: Franklin M, Druyts E. ICER's assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine. J Manag Care Spec Pharm. 2020 Nov;26(11):1464-1466. doi: 10.18553/jmcp.2020.26.11.1464. PMID: 33119438. 18: Huang PC, Yang FC, Chang CM, Yang CP. Targeting the 5-HT1B/1D and 5-HT1F receptors for acute migraine treatment. Prog Brain Res. 2020;255:99-121. doi: 10.1016/bs.pbr.2020.05.010. Epub 2020 Jun 12. PMID: 33008517. 19: Tfelt-Hansen P. Pharmacological strategies to treat attacks of episodic migraine in adults. Expert Opin Pharmacother. 2021 Feb;22(3):305-316. doi: 10.1080/14656566.2020.1828347. Epub 2020 Oct 9. PMID: 33003955. 20: Joyner KR, Morgan KW. Novel Therapies in Acute Migraine Management: Small- Molecule Calcitonin Gene-Receptor Antagonists and Serotonin 1F Receptor Agonist. Ann Pharmacother. 2020 Sep 29:1060028020963574. doi: 10.1177/1060028020963574. Epub ahead of print. PMID: 32993366.